Passage Bio Shares Up After FDA Clears IND Application
June 08 2022 - 8:33AM
Dow Jones News
By Michael Dabaie
Passage Bio Inc. said the U.S. Food and Drug Administration
cleared its investigational new-drug application for PBML04 for the
treatment of metachromatic leukodystrophy.
Shares were up 3.1% to $2.67 premarket Wednesday.
MLD is a rare, fatal pediatric lysosomal storage disease that
currently has limited available treatment options, the company
said.
"We are thrilled to have received IND clearance for our program
in metachromatic leukodystrophy, marking our fourth IND clearance
as a company and our third pediatric lysosomal storage disorder
program to reach clinical development," Edgar Cale, interim chief
executive officer, said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 08, 2022 08:18 ET (12:18 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2023 to Sep 2024